Big Bets and Strategic Moves Drive Biotech Investment in 2025 1 year ago JohnIn InvestmentsLeadersPartnerships
Laquinimod Eye Drops Show Safety and Penetration in Phase I LION Trial 1 year ago JohnIn Clinical TrialsTop Stories
Emerging Clinical Research Highlights Innovation and Regulatory Progress 1 year ago JohnIn Clinical TrialsDeals
Phase II Trial of Novel Radiopharmaceutical NeoB-GRP Shows Early Promise in Prostate Cancer 1 year ago JohnIn Biopharma HighlightsTop Stories
TrialMatchAI Demonstrates Strong Patient-to-Trial Matching Capabilities for Oncology Studies 1 year ago JohnIn AI & DataClinical Trials
Vera Therapeutics and Minovia Push Forward in Clinical Development 1 year ago JohnIn Research UpdatesTop Stories
AC Immune and Edgewise Therapeutics Report Promising Clinical Progress 1 year ago JohnIn BreakthroughsClinical Trials
MAIA Biotechnology Sets Its Sights on Bold Cancer Immunotherapy Milestones for 2025 1 year ago JohnIn Breaking NewsFDA ApprovalsLeadersResearch UpdatesTop Stories
MaaT Pharma Presents Promising Preclinical Data for Next-Gen Microbiome Therapy MaaT034 at AACR 1 year ago JohnIn Biopharma HighlightsClinical TrialsFunding RoundsInnovation
Gene-Silencing Therapy Lepodisiran Shows Major Reduction in Lipoprotein(a); Spinogenix Opens Phase 2 Schizophrenia Trial 1 year ago JohnIn Biopharma HighlightsClinical TrialsInnovationResearch Updates
FDA Leadership Change Sparks Industry Concern as Pharma Navigates Regulatory Challenges 1 year ago JohnIn Biopharma HighlightsInnovationLeadersPharma Industry Updates
FDA Approves Fitusiran for Hemophilia A and B; Vertex Halts VX-264 Type 1 Diabetes Trial 1 year ago JohnIn Clinical TrialsFDA ApprovalsInnovationPharma Industry Updates
FDA Approves Fitusiran (Qfitlia) – First RNAi Therapeutic for Hemophilia A and B; Vertex Halts VX-264 T1D Trial 1 year ago JohnIn Clinical TrialsFDA ApprovalsInnovationPharma Industry Updates
MaaT Pharma Completes €13 Million Capital Increase; Highlights 2024 Progress and 2025 Growth Plans 1 year ago JohnIn Biopharma HighlightsClinical TrialsFunding RoundsInnovationPharma Industry Updates
Viking Therapeutics Reports Full Enrollment in Phase 2 Oral Obesity Drug Trial; Bluejay Therapeutics Advances in Neurological Research 1 year ago JohnIn Clinical TrialsInnovationPharma Industry UpdatesResearch Updates
